Caxton Associates LP Biogen Inc. Transaction History

Caxton Associates LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$222.59 - $267.94 $10 Million - $12.1 Million	45,000 New	45,000 $11.6 Million
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $451,871 - $569,334	-2,332 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $522,181 - $671,079	2,332 New	2,332 $559,000
Q4 2020 Feb 16, 2021	SELL	$236.26 - $355.63 $262,248 - $394,749	-1,110 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $58,778 - $67,867	-222 Reduced 16.67%	1,110 $315,000
Q2 2020 Aug 14, 2020	SELL	$258.66 - $342.55 $1.02 Million - $1.35 Million	-3,943 Reduced 74.75%	1,332 $356,000
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $1.42 Million - $1.8 Million	5,275 New	5,275 $1.67 Million
Q4 2018 Feb 14, 2019	SELL	$278.5 - $352.75 $1.63 Million - $2.07 Million	-5,867 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $1.72 Million - $2.25 Million	5,867 New	5,867 $2.07 Million
Q2 2018 Aug 14, 2018	SELL	$257.52 - $306.91 $687,835 - $819,756	-2,671 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$260.13 - $367.91 $50,725 - $71,742	-195 Reduced 6.8%	2,671 $731,000
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $881,696 - $987,566	2,866 New	2,866 $913,000
Q3 2017 Nov 14, 2017	SELL	$281.15 - $329.69 $421,724 - $494,535	-1,500 Closed	0 $0
Q2 2017 Aug 29, 2017	BUY	N/A	1,500	1,500 $407,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.